129 related articles for article (PubMed ID: 25182961)
21. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Sekine M; Nagata H; Tsuji S; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Tanaka K;
Clin Cancer Res; 2001 Oct; 7(10):3144-50. PubMed ID: 11595708
[TBL] [Abstract][Full Text] [Related]
22. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
Pelttari LM; Kiiski J; Nurminen R; Kallioniemi A; Schleutker J; Gylfe A; Aaltonen LA; Leminen A; Heikkilä P; Blomqvist C; Bützow R; Aittomäki K; Nevanlinna H
J Med Genet; 2012 Jul; 49(7):429-32. PubMed ID: 22652533
[TBL] [Abstract][Full Text] [Related]
23. Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.
Plakhins G; Irmejs A; Gardovskis A; Subatniece S; Rozite S; Bitina M; Keire G; Purkalne G; Teibe U; Trofimovics G; Miklasevics E; Gardovskis J
BMC Med Genet; 2011 Oct; 12():147. PubMed ID: 22032251
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
25. Novel BRCA1 deleterious mutation (c.1918C>T) in familial breast and ovarian cancer syndrome who share a common ancestry.
Gabaldó Barrios X; Sarabia Meseguer MD; Alonso Romero JL; Marín Vera M; Marín Zafra G; Sánchez Henarejos P; Sánchez Bermúdez AI; Ruiz Espejo F
Fam Cancer; 2014 Sep; 13(3):431-5. PubMed ID: 24633894
[TBL] [Abstract][Full Text] [Related]
26. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Górski B
Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
[TBL] [Abstract][Full Text] [Related]
27. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
28. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
Bjørnslett M; Knappskog S; Lønning PE; Dørum A
BMC Cancer; 2012 Oct; 12():454. PubMed ID: 23039163
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
[TBL] [Abstract][Full Text] [Related]
30. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.
Nené NR; Reisel D; Leimbach A; Franchi D; Jones A; Evans I; Knapp S; Ryan A; Ghazali S; Timms JF; Paprotka T; Bjørge L; Zikan M; Cibula D; Colombo N; Widschwendter M
Lancet Oncol; 2019 Aug; 20(8):1171-1182. PubMed ID: 31300207
[TBL] [Abstract][Full Text] [Related]
31. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Johannsson O; Ostermeyer EA; Håkansson S; Friedman LS; Johansson U; Sellberg G; Brøndum-Nielsen K; Sele V; Olsson H; King MC; Borg A
Am J Hum Genet; 1996 Mar; 58(3):441-50. PubMed ID: 8644702
[TBL] [Abstract][Full Text] [Related]
32. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
[TBL] [Abstract][Full Text] [Related]
33. First Two Cases of Bloom Syndrome in Russia: Lack of Skin Manifestations in a
Suspitsin EN; Sibgatullina FI; Lyazina LV; Imyanitov EN
Mol Syndromol; 2017 Mar; 8(2):103-106. PubMed ID: 28611551
[TBL] [Abstract][Full Text] [Related]
34. The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.
Konecny M; Vizvaryova M; Weismanova E; Ilencikova D; Mlkva I; Weismann P; Machackova G; Kausitz J
Neoplasma; 2007; 54(2):137-42. PubMed ID: 17319787
[TBL] [Abstract][Full Text] [Related]
35. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
Kiiski JI; Pelttari LM; Khan S; Freysteinsdottir ES; Reynisdottir I; Hart SN; Shimelis H; Vilske S; Kallioniemi A; Schleutker J; Leminen A; Bützow R; Blomqvist C; Barkardottir RB; Couch FJ; Aittomäki K; Nevanlinna H
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15172-7. PubMed ID: 25288723
[TBL] [Abstract][Full Text] [Related]
36. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
37. German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
Hamann U; Brauch H; Garvin AM; Bastert G; Scott RJ
Genes Chromosomes Cancer; 1997 Feb; 18(2):126-32. PubMed ID: 9115962
[TBL] [Abstract][Full Text] [Related]
38. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Van Der Looij M; Szabo C; Besznyak I; Liszka G; Csokay B; Pulay T; Toth J; Devilee P; King MC; Olah E
Int J Cancer; 2000 Jun; 86(5):737-40. PubMed ID: 10797299
[TBL] [Abstract][Full Text] [Related]
40. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
